Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XORTX TherapeuticsSTU:ANUA -0.79%26 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates STU:ANUA with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 940 Biotechnology companies, XORTX Therapeutics ranks worse than 106382.87% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. XORTX Therapeutics's EBITDA for the
three
months ended in Mar. 2026 was €-0.69 Mil. XORTX Therapeutics's Revenue for the
three
months ended in Mar. 2026 was €0.00 Mil. Therefore, XORTX Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
XORTX Therapeutics EBITDA Margin % Related Terms
XORTX Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for XORTX Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ANUA vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, XORTX Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XORTX Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where XORTX Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XORTX Therapeutics (STU:ANUA) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on XORTX Therapeutics and its competitors. According to the industry distribution chart, XORTX Therapeutics ranks #999999 out of 940 companies in the Biotechnology industry.
Is XORTX Therapeutics' EBITDA Margin % too high?
XORTX Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, XORTX Therapeutics ranks #999999 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, XORTX Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does XORTX Therapeutics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, XORTX Therapeutics ranks #999999 out of 940 companies for EBITDA Margin %. This places XORTX Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on XORTX Therapeutics and its competitors. XORTX Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XORTX Therapeutics stock overvalued right now?
XORTX Therapeutics (STU:ANUA) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. XORTX Therapeutics' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For XORTX Therapeutics (STU:ANUA), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
26GF Score
Get the complete analysis for STU:ANUA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ANUA has been successfully added to your 
